Evotec and Almirall enter into research collaboration in the field of dermatological diseases

Collaboration is focused on first-in-class therapies to treat dermatological diseases Collaboration leverages a novel approach to disrupt cell signalling, validated by EVT Innovate

Topics: Corporate, Evotec, Almirall Read More

Evotec AG listed in MDAX

Dual-listing of Evotec AG share in TecDAX and MDAX as of 24 September 2018 

Topics: Corporate, Evotec Read More

Evotec and Celgene enter partnership in the field of targeted protein degradation

The collaboration will focus on targeted protein degradation Evotec's panomics and data analytics platforms will be leveraged Financials include upfront payment as well as significant potential milestone-based payments and royalties

Topics: Corporate, Celgene, Evotec Read More

Yumanity Therapeutics announces first clinical candidate for the potential treatment of Parkinson’s disease

First-in-Human Trials Planned for the Fourth Quarter of 2019 IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform

Topics: Corporate, IND Enabling, INDiGO, Evotec, Yumanity Therapeutics, Parkinson's disease Read More

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease

Strategic alliance with CHDI to accelerate development of drugs for Huntington's disease One of the largest strategic drug discovery alliances within Evotec 

Topics: Corporate, Evotec, CHDI, Huntington's disease Read More

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Drug Discovery, IPSC, Evotec, CENTOGENE, rare genetic diseases Read More

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

Topics: Corporate, Drug Development, Drug Discovery, Evotec, diabetes, Novo Nordisk, Obesity Read More

Evotec partner Haplogen enters into collaboration with Bayer

Focus on pulmonary diseases with high unmet medical need Integrated Haplogen-Bayer collaboration builds upon pulmonary portfolio created by Evotec and Haplogen Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Bayer to Haplogen

Topics: Corporate, Bayer, Evotec, pulmonary diseases, Haplogen Read More

Evotec repays 50% of € 140 m acquisition loan

Strong operational cashflow facilitates repayment of € 70 M within the first year of the loan term € 140 M loan was taken to expand Evotec's value chain with Aptuit in August 2017

Topics: Corporate, Evotec, Aptuit Read More

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer

Hamburg, Germany, 19 July 2018: Hamburg, Germany, 19 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development ...

Topics: Corporate, Bayer, Endometriosis, Evotec, Chronic cough Read More